Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia.
Mutations in the thymidine kinase gene (tk) of herpes simplex virus type 1 (HSV-1) explain most cases of virus resistance to acyclovir (ACV) treatment. Mucocutaneous lesions of patients with ACV resistance contain mixed populations of tk mutant and wild-type virus. However, it is unknown whether human ganglia also contain mixed populations since the replication of HSV tk mutants in animal neurons is impaired. Here we report the detection of mutated HSV tk sequences in human ganglia. Trigeminal and dorsal root ganglia were obtained at autopsy from an immunocompromised woman with chronic mucocutaneous infection with ACV-resistant HSV-1. The HSV-1 tk open reading frames from ganglia were amplified by PCR, cloned, and sequenced. tk mutations were detected in a seven-G homopolymer region in 11 of 12 ganglia tested, with clonal frequencies ranging from 4.2 to 76% HSV-1 tk mutants per ganglion. In 8 of 11 ganglia, the mutations were heterogeneous, varying from a deletion of one G to an insertion of one to three G residues, with the two-G insertion being the most common. Each ganglion had its own pattern of mutant populations. When individual neurons from one ganglion were analyzed by laser capture microdissection and PCR, 6 of 14 HSV-1-positive neurons were coinfected with HSV tk mutants and wild-type virus, 4 of 14 were infected with wild-type virus alone, and 4 of 14 were infected with tk mutant virus alone. These data suggest that diverse tk mutants arise independently under drug selection and establish latency in human sensory ganglia alone or together with wild-type virus.
Wang
Kening
K
Medical Virology Section, Laboratory of Clinical Infectious Disease, NIAID/NIH, Building 10, Room 11N-234, 10 Center Dr., Bethesda, MD 20892, USA. kwang@niaid.nih.gov
Mahalingam
Gowtham
G
Hoover
Susan E
SE
Mont
Erik K
EK
Holland
Steven M
SM
Cohen
Jeffrey I
JI
Straus
Stephen E
SE
D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics*; D005727:Ganglia, Spinal / Q000201:enzymology / Q000473:pathology / Q000821:virology*; D006561:Herpes Simplex / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D018259:Herpesvirus 1, Human / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D009475:Neurons, Afferent / Q000201:enzymology / Q000473:pathology / Q000821:virology; D017354:Point Mutation; D013937:Thymidine Kinase / Q000235:genetics* / Q000378:metabolism; D014278:Trigeminal Nuclei / Q000201:enzymology / Q000473:pathology / Q000821:virology*; D014764:Viral Proteins / Q000235:genetics* / Q000378:metabolism; D017735:Virus Latency / Q000187:drug effects / Q000235:genetics
D000998:Antiviral Agents; D014764:Viral Proteins; D013937:Thymidine Kinase; D000212:Acyclovir